Literature DB >> 34822065

Evaluating the performance of clinical and radiological data in predicting prostate cancer in prostate imaging reporting and data system version 2.1 category 3 lesions of the peripheral and the transition zones.

Caterina Gaudiano1, Lorenzo Bianchi2,3, Beniamino Corcioni4, Francesca Giunchi5, Riccardo Schiavina2,3, Federica Ciccarese4, Lorenzo Braccischi4, Arianna Rustici4, Michelangelo Fiorentino5,6, Eugenio Brunocilla2,3, Rita Golfieri4.   

Abstract

PURPOSE: To define the value of clinical and radiological data, using multiparametric magnetic resonance imaging (mpMRI), to predict prostate cancer (PCa) in prostate imaging reporting and data system version 2.1 (PIRADSv2.1) 3 lesions of the peripheral and the transition zones (PZ and TZ).
METHODS: The mpMRI of patients with PIRADSv2.1 3 lesions who had undergone fusion targeted biopsy was reviewed. Morphological pattern, diffusion parameters and vascularisation were evaluated. The radiological/histopathological data of benign and malignant lesions, between the PZ and TZ were compared. Univariate and multivariate analyses were carried out to identify the clinical and radiological data capable of predicting PCa.
RESULTS: One hundred and twenty-three lesions were assessed, 93 (76%) in the PZ and 30 (24%) in the TZ. Of these, 56 (46%) were PCa and 67 (54%) were benign. The majority of the PCas were Grade Group System (GGS) 1 (38%) and GGS 2 (39%); tumours having a GGS ≥ 3 were more frequently in the TZ (p = 0.02). Univariate analysis showed a significant correlation between PCa and prostate volume, prostate-specific antigen (PSA) density, lesion zone and the apparent diffusion coefficient. At multivariate logistic regression PSA density > 0.15 ng/ml/ml {Odds ratio [OR] 2.38; p = 0.001} and lesion zone (i.e. TZ OR 7.55) were independent predictors of PCa (all p ≤ 0.04).
CONCLUSION: In solitary PIRADSv2.1 3 lesions, the most important predictive factor was the location zone, with a much greater risk for TZ lesions.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Multiparametric magnetic resonance imaging; PIRADS 3 lesions; PIRADS version 2.1; Prostate cancer

Mesh:

Year:  2021        PMID: 34822065     DOI: 10.1007/s11255-021-03071-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  33 in total

Review 1.  A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer.

Authors:  Li Zhang; Min Tang; Sipan Chen; Xiaoyan Lei; Xiaoling Zhang; Yi Huan
Journal:  Eur Radiol       Date:  2017-06-27       Impact factor: 5.315

Review 2.  State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.

Authors:  Riccardo Schiavina; Francesco Chessa; Marco Borghesi; Caterina Gaudiano; Lorenzo Bianchi; Beniamino Corcioni; Paolo Castellucci; Francesco Ceci; Isabella Ceravolo; Giovanni Barchetti; Maurizio Del Monte; Riccardo Campa; Carlo Catalano; Valeria Panebianco; Cristina Nanni; Stefano Fanti; Andrea Minervini; Angelo Porreca; Eugenio Brunocilla
Journal:  Int J Urol       Date:  2018-09-20       Impact factor: 3.369

3.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.

Authors:  Jeffrey C Weinreb; Jelle O Barentsz; Peter L Choyke; Francois Cornud; Masoom A Haider; Katarzyna J Macura; Daniel Margolis; Mitchell D Schnall; Faina Shtern; Clare M Tempany; Harriet C Thoeny; Sadna Verma
Journal:  Eur Urol       Date:  2015-10-01       Impact factor: 20.096

Review 4.  Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights.

Authors:  Andrea Fandella; Vincenzo Scattoni; Andrea Galosi; Pietro Pepe; Michelangelo Fiorentino; Caterina Gaudiano; Marco Giampaoli; Roberta Gunelli; Pasquale Martino; Vittorino Montanaro; Rodolfo Montironi; Tiziana Pierangeli; Armando Stabile; Alessandro Bertaccini
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.480

Review 5.  Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.

Authors:  Esther H J Hamoen; Maarten de Rooij; J Alfred Witjes; Jelle O Barentsz; Maroeska M Rovers
Journal:  Eur Urol       Date:  2014-11-06       Impact factor: 20.096

6.  Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.

Authors:  Nienke L Hansen; Tristan Barrett; Claudia Kesch; Lana Pepdjonovic; David Bonekamp; Richard O'Sullivan; Florian Distler; Anne Warren; Christina Samel; Boris Hadaschik; Jeremy Grummet; Christof Kastner
Journal:  BJU Int       Date:  2017-11-15       Impact factor: 5.588

Review 7.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

Authors:  Baris Turkbey; Andrew B Rosenkrantz; Masoom A Haider; Anwar R Padhani; Geert Villeirs; Katarzyna J Macura; Clare M Tempany; Peter L Choyke; Francois Cornud; Daniel J Margolis; Harriet C Thoeny; Sadhna Verma; Jelle Barentsz; Jeffrey C Weinreb
Journal:  Eur Urol       Date:  2019-03-18       Impact factor: 20.096

8.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

10.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079

View more
  1 in total

1.  New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3.

Authors:  Chen Huang; Feng Qiu; Di Jin; Xuedong Wei; Zongxin Chen; Ximing Wang; Xiaojun Zhao; Linchuan Guo; Jinxian Pu; Jianquan Hou; Yuhua Huang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.